Coming soon for patients taking XARELTO® (rivaroxaban): Janssen CarePath for XARELTO® and Janssen Select will transition to XARELTO withMe. We are simplifying access to our patient support in one location with a new name and look. Savings card and coverage gap benefits will not change.
Adding XARELTO® to low-dose aspirin
A new diagnosis. Starting therapy. All of this can be daunting and overwhelming. But you can be reassured that, together with a few tips, support, and commitment, it's possible to start on the right track. First things first, be sure to fill your XARELTO® (rivaroxaban) prescription if you haven’t yet.
What is XARELTO®?
XARELTO® belongs to a group of medicines called direct oral anticoagulants, or DOACs for short. Like other DOACs, XARELTO® has no known dietary restrictions, no requirements for frequent blood tests, and few drug interactions.
How does XARELTO® work with aspirin?
Both XARELTO® and aspirin help prevent serious blood clots from forming and growing—but they work in different ways:
- XARELTO® slows your body's ability to clot by selectively blocking one of the clotting factors found in your blood—an enzyme called Factor Xa ("10a").
- Aspirin is an antiplatelet blood thinner that works by helping to keep platelets (which are pieces of blood cells) from sticking together and forming blood clots.
XARELTO® for People With PAD
XARELTO® , in combination with low-dose aspirin, may help reduce the risk of a sudden decrease in blood flow to the legs, major amputation, serious heart problems, and stroke in adults with PAD.
a major blood-clotting
event post vascular intervention.
In a clinical trial,
people with PAD taking XARELTO® 2.5 mg twice daily, in combination with low-dose aspirin once daily, did not have a heart attack or stroke, or die from a cardiovascular event.*
And, in a clinical trial,
almost 85% of people who took XARELTO®, in combination with low-dose aspirin, did not have a heart attack, stroke, sudden decrease in blood flow in the legs, or amputation after vascular intervention.‡
*The rate of the first event like a stroke, heart attack, or cardiovascular death was 5.1% for people taking XARELTO® plus aspirin vs 6.9% for aspirin alone. Patients were followed for an average of 23 months.
‡The rate of the first event like a stroke, heart attack, poor blood flow in the legs, and amputation was 15.5% for people taking XARELTO® plus aspirin vs 17.8% for aspirin alone. Patients were followed for an average length of treatment of 30 months.
Remember, all blood thinners come with a risk of bleeding. Around 3% of people taking XARELTO® 2.5 mg twice daily in combination with low-dose aspirin experienced a major bleeding event, such as bleeding into the brain. That represents about a 1% increase in bleeding versus people taking only low-dose aspirin.
Less than 2% of people taking XARELTO®, in combination with aspirin, experienced a major bleeding versus 1% of people taking only low-dose aspirin.